Journal article

Authors list: Harker-Murray, Paul; Mauz-Koerholz, Christine; Leblanc, Thierry; Mascarin, Maurizio; Michel, Gerard; Cooper, Stacy; Beishuizen, Auke; Leger, Kasey J.; Amoroso, Loredana; Buffardi, Salvatore; Rigaud, Charlotte; Hoppe, Bradford S.; Lisano, Julie; Francis, Stephen; Sacchi, Mariana; Cole, Peter D.; Drachtman, Richard A.; Kelly, Kara M.; Daw, Stephen

Publication year: 2023

Pages: 2075-2084

Journal: Blood

Volume number: 141

Issue number: 17

ISSN: 0006-4971

eISSN: 1528-0020

Open access status: Hybrid

DOI Link: https://doi.org/10.1182/blood.2022017118

Publisher: American Society of Hematology (ASH Publications)

Abstract: 
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744, a phase 2 study for CAYA (aged 5-30 years) with R/R cHL, evaluated a risk-stratified, response-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response. Risk stratification was pri-marily based on time to relapse, prior treatment, and presence of B symptoms. We present the primary analysis of the standard-risk cohort. Data from the low-risk cohort are reported separately. Patients received 4 induction cycles with nivolumab plus BV; those without CMR (Deauville score >3, Lugano 2014) received BV plus bendamustine intensification. Patients with CMR after induction or intensification proceeded to consolidation (high-dose chemotherapy/auto-HCT per protocol). Primary end point was CMR any time before consolidation. Forty-four patients were treated. Median age was 16 years. At a minimum follow-up of 15.6 months, 43 patients received 4 induction cycles (1 discontinued), 11 of whom received intensification; 32 proceeded to consolidation. CMR rate was 59% after induction with nivolumab plus BV and 94% any time before consolidation (nivolumab plus BV +/- BV plus bendamustine). One-year progression-free survival rate was 91%. During induction, 18% of patients experienced grade 3/4 treatment-related adverse events. This risk-stratified, response-adapted salvage strategy had high CMR rates with limited toxicities in CAYA with R/R cHL. Most patients did not require additional chemotherapy (bendamustine intensification). Additional follow-up is needed to confirm durability of disease control.

Harvard Citation style: Harker-Murray, P., Mauz-Koerholz, C., Leblanc, T., Mascarin, M., Michel, G., Cooper, S., et al. (2023) Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults, Blood, 141(17), pp. 2075-2084. https://doi.org/10.1182/blood.2022017118

APA Citation style: Harker-Murray, P., Mauz-Koerholz, C., Leblanc, T., Mascarin, M., Michel, G., Cooper, S., Beishuizen, A., Leger, K., Amoroso, L., Buffardi, S., Rigaud, C., Hoppe, B., Lisano, J., Francis, S., Sacchi, M., Cole, P., Drachtman, R., Kelly, K., & Daw, S. (2023). Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 141(17), 2075-2084. https://doi.org/10.1182/blood.2022017118